Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Balaxi Pharmaceuticals Ltd (BALAXI)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BALAXI Trading | Small Cap | Balaxi Pharma. Share Price
BSE Share Price
Not Listed
Not Listed
Balaxi Pharmaceuticals Ltd (BALAXI)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BALAXI Trading | Small Cap | Balaxi Pharma. Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹126 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹0.4
TTM Sales
₹280 Cr.
Book Value per Share
₹45.4
P/E Ratio
51.97
Higher than its 5-year historical median
Industry PE
39.4
Price to Book (P/B)
0.50
Lower than its 5-year historical median
Price to Sales (P/S)
0.45
Lower than its 5-year historical median
EV/EBITDA
13.22
Lower than its 5-year historical median
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
0.59%
Underperforms industry median
Return on Capital Employed (ROCE)
3.48%
Underperforms industry median
Return on Assets (ROA)
0.44%
Operating Profit Margin
3.5%
Net Profit Margin
0.52%
Gross Profit Margin
2.8%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
32.56%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-70.27%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-94.34%
Asset Quality
Promoter Holding
65.99%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹239 Cr.
Equity
₹11 Cr.
Face Value
₹2
All Time Low / High
₹0.00 / 0.00
Check Before You Invest
Quality
Somewhat GoodValuation
UndervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Balaxi Pharmaceuticals Ltd a good quality company?
Balaxi Pharmaceuticals Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Balaxi Pharmaceuticals Ltd performance compare with that of its Peers?
Revenue growth of Balaxi Pharmaceuticals Ltd vs industry peers?
Balaxi Pharmaceuticals Ltd revenue CAGR is 3.15%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Balaxi Pharmaceuticals Ltd?
Promoters hold 65.99% of the Balaxi Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Balaxi Pharmaceuticals Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of -47.55% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Balaxi Pharmaceuticals Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -4.7% | -39.7% | 96.2% | 58.4% | 55.4% | 37.1% | 28.2% | 6.1% | 5.1% | 6.1% | - |
| Value Creation Index ⓘ | -1.3 | -3.8 | 5.9 | 3.2 | 3.0 | 1.7 | 1.0 | -0.6 | -0.6 | -0.6 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 0 | 13.6 | 45.6 | 86.9 | 101 | 108 | 70.2 | 61 | 80.9 | 80 |
| Sales YoY Gr. | - | NA | NA | 235.5% | 90.4% | 16.6% | 6.8% | -35.1% | -13.1% | 32.6% | - |
| Adj EPS ⓘ | -0.1 | -0.5 | 1.3 | 1.2 | 2.8 | 2.6 | 2.4 | 0.5 | 0.3 | -0.1 | 0.7 |
| YoY Gr. | - | NA | NA | -8.3% | 129.5% | -8.9% | -6.7% | -81.1% | -40% | -122.2% | - |
| BVPS (₹) ⓘ | 1.5 | 1 | 2.3 | 5.6 | 8.7 | 11.6 | 16.1 | 21.6 | 23.2 | 24.1 | 23.9 |
| Adj Net Profit ⓘ | -0.2 | -0.8 | 2 | 6.1 | 14 | 12.8 | 12.1 | 2.5 | 1.5 | -0.3 | 4 |
| Cash Flow from Ops. ⓘ | -0.1 | -0.7 | -1.5 | -14.4 | 13.5 | 8.9 | -7.1 | -1.8 | -7.6 | 43.9 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0.3 | 0.2 | -1.5 | -7.6 | -4 | 0.8 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | -1.4% | -9.2% | 32.6% | ||||
| Adj EPS ⓘ | NA | -146.4% | -129.3% | -122.2% | ||||
| BVPSⓘ | 35.8% | 22.7% | 14.5% | 4% | ||||
| Share Price | - | -47.6% | -63.1% | -47.1% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -6.4 | -39.6 | 79.7 | 38.6 | 39.2 | 25.2 | 16.2 | 2.3 | 1.2 | -0.3 | 2.8 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 12 | 19 | 21.9 | 17.1 | 15.6 | 7.7 | 4.3 | 1.2 | -1 |
| Net Profit Mgn % ⓘ | 0 | 0 | 14.9 | 13.4 | 16.1 | 12.6 | 11.2 | 3.5 | 2.5 | -0.4 | 4.6 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0.1 | 0 | 0.1 | 0.1 | 0.2 | 0.3 | - |
| Working Cap Days ⓘ | 0 | 0 | 80 | 160 | 173 | 193 | 237 | 423 | 518 | 356 | 188 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 39 | 103 | 103 | 108 | 154 | 322 | 432 | 284 | 61 |
Valuation of Balaxi Pharma. - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 14 | 46 | 231 | 279 | 336 | 241 | 293 | 270 |
| Operating Expenses ⓘ + | 12 | 37 | 189 | 229 | 279 | 197 | 260 | 261 |
| Operating Profit ⓘ | 2 | 8 | 43 | 51 | 57 | 45 | 32 | 10 |
| Operating Profit Margin (%) | 11.5% | 18.1% | 18.4% | 18.2% | 17.1% | 18.5% | 11.0% | 3.5% |
| Other Income ⓘ + | 1 | 1 | 2 | 5 | 3 | 1 | 2 | 3 |
| Interest ⓘ | 0 | 0 | 0 | 1 | 1 | 3 | 4 | 5 |
| Depreciation ⓘ | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit Before Tax ⓘ | 2 | 9 | 44 | 55 | 57 | 2 | 29 | 5 |
| Tax ⓘ | 0 | 3 | 6 | 7 | 11 | 4 | 4 | 4 |
| Profit After Tax | 2 | 6 | 38 | 48 | 46 | -2 | 25 | 1 |
| PAT Margin (%) | 14.5% | 13.4% | 16.5% | 17.1% | 13.7% | -1.0% | 8.6% | 0.5% |
| Adjusted EPS (₹) | 1.3 | 1.2 | 7.5 | 9.6 | 10.2 | -1.3 | 5.0 | 3.1 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 1% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 4 | 28 | 65 | 113 | 173 | 198 | 232 | 249 | |||
| Debt + | 0 | 0 | 4 | 4 | 12 | 18 | 52 | 56 | |||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Trade Payables | 2 | 5 | 25 | 49 | 35 | 29 | 16 | 21 | |||
| Others Liabilities ⓘ | 1 | 3 | 6 | 11 | 21 | 14 | 11 | 11 | |||
| Total Liabilities ⓘ | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 337 | |||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 0 | 0 | 2 | 29 | 41 | 41 | 41 | 82 | |||
| CWIP ⓘ | 0 | 0 | 0 | 1 | 3 | 2 | 22 | 0 | |||
| Investments ⓘ | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | |||
| Inventories | 0 | 1 | 14 | 99 | 105 | 82 | 78 | 83 | |||
| Trade Receivables | 5 | 30 | 77 | 28 | 52 | 56 | 111 | 136 | |||
| Cash Equivalents | 0 | 4 | 2 | 7 | 28 | 62 | 39 | 15 | |||
| Others Assets ⓘ | 0 | 1 | 2 | 14 | 10 | 15 | 19 | 21 | |||
| Total Assets ⓘ | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 337 | |||
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -2 | -14 | 0 | 34 | 6 | 5 | -35 | -4 |
| Cash Flow From Investing Activity ⓘ + | -0 | -0 | -6 | -28 | -11 | -1 | -22 | -21 |
| Cash Flow From Financing Activity ⓘ + | 0 | 18 | 4 | -0 | 26 | 30 | 34 | 0 |
| Net Cash Flow ⓘ | -2 | 4 | -2 | 6 | 21 | 34 | -23 | -25 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 55.84 | 39.04 | 82.26 | 53.5 | 32.17 | -1.29 | 11.68 | 0.59 | ||
| ROCE (%) | 69.35 | 56.56 | 92.56 | 59.62 | 37.46 | 2.31 | 13.01 | 3.48 | ||
| Asset Turnover Ratio | 2.23 | 2.17 | 3.41 | 2.02 | 1.62 | 0.97 | 1.03 | 0.83 | ||
| PAT to CFO Conversion(x) | -1 | -2.33 | 0 | 0.71 | 0.13 | N/A | -1.4 | -4 | ||
| Working Capital Days | ||||||||||
| Receivable Days | 147 | 140.70 | 84 | 68.10 | 43.30 | 81.70 | 103.90 | 166.80 | ||
| Inventory Days | 0 | 6.70 | 11.40 | 73.40 | 110.50 | 141.60 | 100.20 | 109.40 | ||
| Payable Days | 74.20 | 38.50 | 31.50 | 69 | 75.40 | 90.10 | 49.80 | 45.20 | ||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Balaxi Pharmaceuticals Ltd FAQs
The current trading price of Balaxi Pharma. on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Balaxi Pharma. stood at ₹126.0 Cr
The latest P/E ratio of Balaxi Pharma. as of 31-Dec-1969 is 34.05.
The latest P/B ratio of Balaxi Pharma. as of 31-Dec-1969 is 0.96.
The 52-week high of Balaxi Pharma. is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Balaxi Pharma. is ₹79.73 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Balaxi Pharmaceuticals Ltd is a average quality company.
The key valuation ratios of Balaxi Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Balaxi Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Balaxi Pharmaceuticals Ltd
Balaxi Pharmaceuticals Limited is a branded IPR-based pharmaceutical Company focusing on frontier markets, with a vast and growing portfolio of drugs across multiple therapeutic segments. Its markets extend across the continents of Americas, Africa and the Caribbean islands. It is a dynamic and responsible company, with a rich and growing portfolio of branded and generic medicines and consumer products.
Business area of the company
The company is engaged in the business of international wholesale trading of Pharmaceuticals, Builders Hardware and FMCG products
History and Milestones
2003-07
- Commenced Pharmaceutcal business by supplying white labeled products to customers in Africa.
- Sourcing was from WHO GMP certified plants based in India.
2008-10
- Created frontend presence for its Pharmaceutical Business by setting up 1st wholesale depot in Angola in 2008.
2011-13
- Started sourcing pharmaceutical from WHO GMP certified manufacturers in China by setting up an office in China in 2011.
- Opened first wholesale depot for its ancillary business in Angola.
2014-16
- In 2014, the group expanded its pharmaceutical business in Angola by setting up its 12th wholesale depot and a central distribution warehouse.
- Made in-roads in Dominican Republic pharmaceutical market, submitted technical dossiers for securing product registrations and opened a central distribution warehouse.
2017-19
- Set-up central distribution warehouse in Guatemala marking the entry of Balaxi into its third geography.
- Leveraged the vast on-ground infrastructure in Angola by entering branded consumer goods products business in 2019.
2020
- Submitted several technical dossiers of Pharmaceutical products in EL Salvador and Honduras for product registrations.
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
